Evidence map›Paper›PMID 9259587›Full record

ArticleThe Journal of clinical investigation1997

The mitogen-activated protein kinase pathway can mediate growth inhibition and proliferation in smooth muscle cells. Dependence on the availability of downstream targets.

K E Bornfeldt, J S Campbell, H Koyama, G M Argast, C C Leslie, E W Raines, E G Krebs, R Ross

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 148 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Reduced Expression of Glutathione S-TransferaseJournal of the American Society of Nephrology : JASN · 2018
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

K E BornfeldtDepartment of Pathology, University of Washington, Seattle, Washington 98195, USA. bornf@u.washington.edu
J S Campbell
H Koyama
G M Argast
C C Leslie
E W Raines
E G Krebs
R Ross
University of Washington · USNational Jewish Health · US

Funding

VLA-4 and VCAM-1 in Advanced AtherosclerosisP01HL018645 · NHLBI · UNIVERSITY OF WASHINGTON · PI HARLAN, JOHN MARSHALL · 1985 to 2010
$23.9M
SPECIALIZED CENTER OF RESEARCH IN ARTERIOSCLEROSISP50HL047151 · NHLBI · UNIVERSITY OF WASHINGTON · PI ALPERS, CHARLES E · 1992 to 1996
–
LINKING OF PROTEIN TYROSINE AND SERINE PHOSPHORYLATIONR01DK042528 · NIDDK · UNIVERSITY OF WASHINGTON · PI KREBS, EDWIN G. · 1990 to 1999
–
NHLBI NIH HHS HL-18645NHLBI NIH HHS HL-47151NIDDK NIH HHS DK-42528
6 · The paper itself

Abstract

Activation of the classical mitogen-activated protein kinase (MAPK) pathway leads to proliferation of many cell types. Accordingly, an inhibitor of MAPK kinase, PD 098059, inhibits PDGF-induced proliferation of human arterial smooth muscle cells (SMCs) that do not secrete growth-inhibitory PGs such as PGE2. In striking contrast, in SMCs that express the inducible form of cyclooxygenase (COX-2), activation of MAPK serves as a negative regulator of proliferation. In these cells, PDGF-induced MAPK activation leads to cytosolic phospholipase A2 activation, PGE2 release, and subsequent activation of the cAMP-dependent protein kinase (PKA), which acts as a strong inhibitor of SMC proliferation. Inhibition of either MAPK kinase signaling or of COX-2 in these cells releases them from the influence of the growth-inhibitory PGs and results in the subsequent cell cycle traverse and proliferation. Thus, the MAPK pathway mediates either proliferation or growth inhibition in human arterial SMCs depending on the availability of specific downstream enzyme targets.

Indexed as

Cell DivisionCyclic AMP-Dependent Protein KinasesCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDinoprostoneDNADose-Response Relationship, DrugEnzyme InhibitorsFlavonoidsHumansIndomethacinIsoenzymesMAP Kinase Kinase 1Membrane ProteinsMitogen-Activated Protein Kinase Kinases2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-oneCyclic AMP-Dependent Protein KinasesCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDinoprostoneDNAEnzyme InhibitorsFlavonoidsIndomethacinIsoenzymesMAP2K1 protein, humanMAP Kinase Kinase 1Membrane ProteinsMitogen-Activated Protein Kinase KinasesPhospholipases APhospholipases A2Platelet-Derived Growth FactorProstaglandin-Endoperoxide SynthasesProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesPTGS2 protein, human

Identifiers

PMID9259587
PMCPMC508260
OpenAlexW1970061904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.